• Informed consent was obtained to participate in the trial

• Body weight ≥45 kg, BMI 18-33 kg/m2 (both ends included)

• The 12-lead ECG was normal or abnormal but clinically insignificant until randomization

• Contraception was strict from the time informed consent was signed until 1 month (for subjects receiving HRS-9821/ placebo) or 3 months (for male subjects receiving moxifloxacin) after the last dose

• All study regulations and procedures were followed and inhalation devices used in the study were used correctly during the study

• The following inclusion criteria apply only to healthy subjects:

• Vital signs were normal at screening

• Pulmonary function was normal during screening

• No smoking or smoking cessation ≥12 months before screening, and previous smoking history \<5 pack-years；

• Healthy male 18-50 years old The following inclusion criteria apply only to subjects with COPD

⁃ Male or female, aged 40-75 years;

⁃ Patients diagnosed with COPD;

⁃ A post-bronchodilator FEV1 /FVC \< 0.7,40% ≤FEV1 \< 80% of the predicted value,;

⁃ Smoking history of≥ 10 pack-years;

⁃ Normal chest X-ray examination results at screening;

⁃ Supporting discontinuation of COPD-related medications before randomization；